RPL35A

Across TCGA pan-cancer cohorts, RPL35A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPL35A data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL35A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL35A expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where RPL35A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.773	0.414	<.001	40	view →
UCEC	OS	Tertile	III,IV	1.000	0.311	.023	30	view →
PDAC	DFS	Tertile	III,IV	0.363	0.821	.015	6	view →
HNSC	DFS	Tertile	II,III,IV	0.870	0.695	.026	4	view →
GBM	DFS	Quartile	All	0.227	0.502	.010	3	view →
CCRCC	OS	Tertile	All	0.655	1.000	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL35A–LUAD (DFS)

Open the LUAD breakdown →